Carotid intima-media thickness, fibroblast growth factor 23, and mineral bone disorder in children with chronic kidney disease.
Humans
Fibroblast Growth Factor-23
Child
Carotid Intima-Media Thickness
Male
Fibroblast Growth Factors
/ blood
Female
Cross-Sectional Studies
Renal Insufficiency, Chronic
/ blood
Child, Preschool
Adolescent
Bone Diseases, Metabolic
/ epidemiology
Chronic Kidney Disease-Mineral and Bone Disorder
/ blood
Calcium
Dialysis
End-stage kidney disease
Hypertension
Left ventricular hypertrophy
Parathyroid hormone
Phosphorus
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
received:
15
12
2023
accepted:
23
09
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
21
10
2024
Statut:
epublish
Résumé
Carotid intima-media thickness (cIMT) is a measure of atherosclerotic vascular disease and a surrogate biomarker for cardiovascular risk in patients with chronic kidney disease (CKD). Mineral and bone disorders (MBD) are complications of CKD, contributing to vascular calcification and accelerated atherosclerosis. Increased fibroblast growth factor 23 (FGF23)-the earliest detectable serum abnormality associated with CKD-MBD-has been linked with cardiovascular disease in patients with CKD. This study aimed to identify factors and analyze the relationship associated with high cIMT, high FGF23, and poor MBD control in children with CKD. A cross-sectional study was conducted in Yogyakarta, Indonesia recruiting children with CKD. The correlations and factors between cIMT, FGF23, and MBD were explored. We recruited 42 children aged 2-18 years old with CKD stages 2 to 5D. There were no significant correlations between cIMT and factors including advanced CKD, use of dialysis, body mass index, hypertension, anemia, MBD, FGF23 levels, and left ventricular mass index (LVMI). Patients with advanced CKD had poorly controlled anemia, hypertension, and higher LVMI. In multivariate analysis, CKD stages, hypertension stages, the presence of MBD, and LVMI were associated with FGF23 levels (p < 0.05). FGF23 levels increased with CKD progression, and MBD was more prevalent in advanced kidney disease. Elevated FGF23 is potentially associated with increased MBD prevalence in late-stage CKD. A larger study is needed to confirm the factors affecting cIMT in children with CKD.
Sections du résumé
BACKGROUND
BACKGROUND
Carotid intima-media thickness (cIMT) is a measure of atherosclerotic vascular disease and a surrogate biomarker for cardiovascular risk in patients with chronic kidney disease (CKD). Mineral and bone disorders (MBD) are complications of CKD, contributing to vascular calcification and accelerated atherosclerosis. Increased fibroblast growth factor 23 (FGF23)-the earliest detectable serum abnormality associated with CKD-MBD-has been linked with cardiovascular disease in patients with CKD. This study aimed to identify factors and analyze the relationship associated with high cIMT, high FGF23, and poor MBD control in children with CKD.
METHODS
METHODS
A cross-sectional study was conducted in Yogyakarta, Indonesia recruiting children with CKD. The correlations and factors between cIMT, FGF23, and MBD were explored.
RESULTS
RESULTS
We recruited 42 children aged 2-18 years old with CKD stages 2 to 5D. There were no significant correlations between cIMT and factors including advanced CKD, use of dialysis, body mass index, hypertension, anemia, MBD, FGF23 levels, and left ventricular mass index (LVMI). Patients with advanced CKD had poorly controlled anemia, hypertension, and higher LVMI. In multivariate analysis, CKD stages, hypertension stages, the presence of MBD, and LVMI were associated with FGF23 levels (p < 0.05).
CONCLUSIONS
CONCLUSIONS
FGF23 levels increased with CKD progression, and MBD was more prevalent in advanced kidney disease. Elevated FGF23 is potentially associated with increased MBD prevalence in late-stage CKD. A larger study is needed to confirm the factors affecting cIMT in children with CKD.
Identifiants
pubmed: 39433982
doi: 10.1186/s12882-024-03771-z
pii: 10.1186/s12882-024-03771-z
doi:
Substances chimiques
Fibroblast Growth Factor-23
7Q7P4S7RRE
Fibroblast Growth Factors
62031-54-3
FGF23 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
369Informations de copyright
© 2024. The Author(s).
Références
Fukagawa M, Komaba H. Chronic kidney disease-mineral and bone disorder in Asia. Kidney Dis (Basel). 2017;3(1):1–7. https://doi.org/10.1159/000470909 .
doi: 10.1159/000470909
pubmed: 28785558
Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children. Clin Kidney J. 2016;9(4):583–91. https://doi.org/10.1093/ckj/sfw047 .
doi: 10.1093/ckj/sfw047
pubmed: 27478602
pmcid: 4957724
Shroff R, Wesseling-Perry K, Bacchetta J. Chronic kidney disease – mineral and bone disorder (CKD-MBD). In: Emma F, Goldstein SL, Bagga A, Bates CM, Shroff R, editors. Pediatric Nephrology. Berlin: Springer; 2002. pp. 1755–83. https://doi.org/10.1007/978-3-030-52719-8_129 .
doi: 10.1007/978-3-030-52719-8_129
Andrews ES, Perrenoud L, Nowak KL, You Z, Pasch A, Chonchol M, et al. Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; a post-hoc analysis of a randomized clinical trial. PLoS ONE. 2018;13(10):e0205831. https://doi.org/10.1371/journal.pone.0205831 .
doi: 10.1371/journal.pone.0205831
pubmed: 30356327
pmcid: 6200237
Lalayiannis AD, Crabtree NJ, Ferro CJ, Wheeler DC, Duncan ND, Smith C, et al. Bone mineral density and vascular calcification in children and young adults with CKD 4 to 5 or on dialysis. Kidney Int Rep. 2022;8(2):265–73. https://doi.org/10.1016/j.ekir.2022.10.023 .
doi: 10.1016/j.ekir.2022.10.023
pubmed: 36815116
pmcid: 9939315
Lawal OM, Balogun MO, Akintomide AO, Ayoola OO, Mene-Afejuku TO, Ogunlade O, et al. Carotid intima-media thickness: a surrogate marker for cardiovascular disease in chronic kidney disease patients. Clin Med Insights Cardiol. 2019;13:1179546819852941. https://doi.org/10.1177/1179546819852941 .
doi: 10.1177/1179546819852941
pubmed: 31258338
pmcid: 6589967
Schaefer F, Doyon A, Azukaitis K, Bayazit A, Canpolat N, Duzova A, et al. Cardiovascular phenotypes in children with CKD: the 4 C study. Clin J Am Soc Nephrol. 2017;12(1):19–28. https://doi.org/10.2215/CJN.01090216 .
doi: 10.2215/CJN.01090216
pubmed: 27827310
Brady TM, Schneider MF, Flynn JT, Cox C, Samuels J, Saland J, et al. Carotid intima-media thickness in children with CKD: results from the CKiD study. Clin J Am Soc Nephrol. 2012;7(12):1930–7. https://doi.org/10.2215/CJN.03130312 .
doi: 10.2215/CJN.03130312
pubmed: 22977209
pmcid: 3513743
Lopes R, Morais MB, Oliveira FLC, Brecheret AP, Abreu ALCS, Andrade MC. Evaluation of carotid intima-media thickness and factors associated with cardiovascular disease in children and adolescents with chronic kidney disease. J Pediatr (Rio J). 2019 Nov-Dec;95(6):696–704. https://doi.org/10.1016/j.jped.2018.06.010 .
Husen M, Fischer A, Lehnhardt A, Klaassen I, Moller K, Muller-Wiefel D, et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int. 2010;78(2):200–6. https://doi.org/10.1038/ki.2010.107 .
doi: 10.1038/ki.2010.107
pubmed: 20407479
Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370–8. https://doi.org/10.1038/ki.2011.47 .
doi: 10.1038/ki.2011.47
pubmed: 21389978
pmcid: 3134393
Palupi-Baroto R, Hermawan K, Murni IK, Nurlitasari T, Prihastuti Y, Sekali DRK, et al. High fibroblast growth factor 23 as a biomarker for severe cardiac impairment in children with chronic kidney disease: a single tertiary center study. Int J Nephrol Renovasc Dis. 2021;14:165–71. https://doi.org/10.2147/IJNRD.S304143 .
doi: 10.2147/IJNRD.S304143
pubmed: 34135617
pmcid: 8197584
Naveh-Many T, Silver J. The pas de trois of vitamin D, FGF23, and PTH. J Am Soc Nephrol. 2017;28(2):393–5. https://doi.org/10.1681/ASN.2016090944 .
doi: 10.1681/ASN.2016090944
pubmed: 27807212
Silver J, Naveh-Many T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol. 2013;9(11):641–9. https://doi.org/10.1038/nrneph.2013.147 .
doi: 10.1038/nrneph.2013.147
pubmed: 23877588
Albanese L, Caliendo G, D’Elia G, Passariello L, Molinari AM, Napoli C, et al. Diagnostic utility of FGF-23 in mineral bone disorder during chronic kidney disease. J Circ Biomark. 2022;11:1–4. https://doi.org/10.33393/jcb.2022.2328 .
doi: 10.33393/jcb.2022.2328
pubmed: 35023876
pmcid: 8749389
Kurpas A, Supeł K, Idzikowska K, Zielińska M. FGF23: a review of its role in mineral metabolism and renal and cardiovascular disease. Dis Markers. 2021;2021:8821292. https://doi.org/10.1155/2021/8821292 .
doi: 10.1155/2021/8821292
pubmed: 34055103
pmcid: 8149241
Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab. 2009;94(2):511–7. https://doi.org/10.1210/jc.2008-0326 .
doi: 10.1210/jc.2008-0326
pubmed: 19050056
Leifheit-Nestler M, Haffner D. How FGF23 shapes multiple organs in chronic kidney disease. Mol Cell Pediatr. 2021;8(1):12. https://doi.org/10.1186/s40348-021-00123-x .
doi: 10.1186/s40348-021-00123-x
pubmed: 34536161
pmcid: 8449753
Hanudel MR, Salusky IB. Treatment of pediatric chronic kidney disease-mineral and bone disorder. Curr Osteoporos Rep. 2017;15(3):198–206. https://doi.org/10.1007/s11914-017-0365-0 .
doi: 10.1007/s11914-017-0365-0
pubmed: 28455644
pmcid: 5607746
Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7(1):146–52. https://doi.org/10.2215/CJN.05940611 .
doi: 10.2215/CJN.05940611
pubmed: 22052943
Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol. 2011;26(6):945–51. https://doi.org/10.1007/s00467-011-1822-0 .
doi: 10.1007/s00467-011-1822-0
pubmed: 21359960
Singh G, Mishra OP, Abhinay A, Agarwal V, Mishra SP, Dwivedi AD, et al. Fibroblast growth factor 23 level and cardiovascular parameters in children with chronic kidney disease. Indian J Pediatr. 2022;89(9):865–71. https://doi.org/10.1007/s12098-021-03927-x .
doi: 10.1007/s12098-021-03927-x
pubmed: 34767187
Preka E, Ranchin B, Doyon A, Vierge M, Ginhoux T, Kassai B, et al. The interplay between bone and vessels in pediatric CKD: lessons from a single-center study. Pediatr Nephrol. 2018;33(9):1565–75. https://doi.org/10.1007/s00467-018-3978-3 .
doi: 10.1007/s00467-018-3978-3
pubmed: 29872964
KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplements. 2013;3:1–150. https://doi.org/10.1038/kisup.2012.77 .
doi: 10.1038/kisup.2012.77
KDIGO Executive Committee. KDIGO 2023 clinical practice guideline for the evaluation and management of chronic kidney disease.
Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904. https://doi.org/10.1542/peds.2017-1904 .
doi: 10.1542/peds.2017-1904
pubmed: 28827377
Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, et al. Fibroblast growth factor 23 and risk of CKD progression in children. Clin J Am Soc Nephrol. 2016;11(11):1989–98. https://doi.org/10.2215/CJN.02110216 .
doi: 10.2215/CJN.02110216
pubmed: 27561289
pmcid: 5108188
Jančič SG, Močnik M, Marčun Varda N. Glomerular filtration rate assessment in children. Child (Basel). 2022;9(12):1995. https://doi.org/10.3390/children9121995 .
doi: 10.3390/children9121995
Drole Torkar A, Plesnik E, Groselj U, Battelino T, Kotnik P. Carotid intima-media thickness in healthy children and adolescents: normative data and systematic literature review. Front Cardiovasc Med. 2020;7:597768. https://doi.org/10.3389/fcvm.2020.597768 .
doi: 10.3389/fcvm.2020.597768
pubmed: 33330658
pmcid: 7732599
Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(2):93–quiz111189. https://doi.org/10.1016/j.echo.2007.11.011 .
doi: 10.1016/j.echo.2007.11.011
pubmed: 18261694
Baroncini LA, Sylvestre Lde C, Pecoits Filho R. Assessment of intima-media thickness in healthy children aged 1 to 15 years. Arq Bras Cardiol. 2016;106(4):327–32. https://doi.org/10.5935/abc.20160030 .
doi: 10.5935/abc.20160030
pubmed: 26959401
pmcid: 4845706
Doyon A, Kracht D, Bayazit AK, Deveci M, Duzova A, Krmar RT, et al. Carotid artery intima-media thickness and distensibility in children and adolescents: reference values and role of body dimensions. Hypertension. 2013;62(3):550–6. https://doi.org/10.1161/HYPERTENSIONAHA.113.01297 .
doi: 10.1161/HYPERTENSIONAHA.113.01297
pubmed: 23817494
Park MK, Park. Pediatric cardiology for practitioners. 6th ed. Philadelphia: Elsevier Saunders; 2016. pp. 210–23.
KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Supplements. 2012;2(4):279–335. https://doi.org/10.1038/kisup.2012.33 .
doi: 10.1038/kisup.2012.33
World Health Organization. Anaemia [Internet], Geneva. WHO; 2023 [cited on 2023 Nov 17]. https://www.who.int/data/nutrition/nlis/info/anaemia
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113S1–130. https://doi.org/10.1038/ki.2009.188 .
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1–59. https://doi.org/10.1016/j.kisu.2017.04.001 .
doi: 10.1016/j.kisu.2017.04.001
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–201. https://doi.org/10.1016/S0272-6386(03)00905-3 .
doi: 10.1016/S0272-6386(03)00905-3
Mayo Clinic Laboratories. Pediatric catalog: Uric acid, serum [Internet]. Minnesota: Mayo Foundation for Medical Education and Research; 2023 [cited on 2023 Nov 15]. https://pediatric.testcatalog.org/show/URIC
Centers for Disease Control and Prevention. Defining child BMI categories [Internet]. Atlanta: CDC. 2023 Mar [cited on 2023 Nov 20]. https://www.cdc.gov/obesity/basics/childhood-defining.html
Drube J, Wan M, Bonthuis M, Wühl E, Bacchetta J, Santos F, et al. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol. 2019;15(9):577–89. https://doi.org/10.1038/s41581-019-0161-4 .
doi: 10.1038/s41581-019-0161-4
pubmed: 31197263
pmcid: 7136166
Ingelfinger JR, Kalantar-Zadeh K, Schaefer F, World Kidney Day Steering Committee. Averting the legacy of kidney disease–focus on childhood. Kidney Int. 2016;89(3):512–8. https://doi.org/10.1016/j.kint.2015.10.014 .
doi: 10.1016/j.kint.2015.10.014
pubmed: 26880442
Baum M. Overview of chronic kidney disease in children. Curr Opin Pediatr. 2010;22(2):158–60. https://doi.org/10.1097/MOP.0b013e32833695cb .
doi: 10.1097/MOP.0b013e32833695cb
pubmed: 20299869
pmcid: 2880183
Ambarsari CG, Utami DAP, Tandri CC, Satari HI. Comparison of three spot proteinuria measurements for pediatric nephrotic syndrome: based on the International Pediatric Nephrology Association 2022 guidelines. Ren Fail. 2023;45(2):2253324. https://doi.org/10.1080/0886022X.2023.2253324 .
doi: 10.1080/0886022X.2023.2253324
pubmed: 37724557
pmcid: 10512887
Ambarsari CG, Cho Y, Milanzi E, Francis A, Koh LJ, Lalji R, et al. Epidemiology and outcomes of children with kidney failure receiving kidney replacement therapy in Australia and New Zealand. Kidney Int Rep. 2023;8(10):1951–64. https://doi.org/10.1016/j.ekir.2023.07.006 .
doi: 10.1016/j.ekir.2023.07.006
pubmed: 37850025
pmcid: 10577490
Wente-Schulz S, Aksenova M, Awan A, Ambarsari CG, Becherucci F, Emma F, et al. Aetiology, course and treatment of acute tubulointerstitial nephritis in paediatric patients: a cross-sectional web-based survey. BMJ Open. 2021;11(5):e047059. https://doi.org/10.1136/bmjopen-2020-047059 .
doi: 10.1136/bmjopen-2020-047059
pubmed: 34049919
pmcid: 8166597
Ambarsari CG, Tambunan T, Pardede SO, Fazlur Rahman FH, Kadaristiana A. Role of dipstick albuminuria in progression of paediatric chronic kidney disease. J Pak Med Assoc. 2021;71(Suppl 2):S103–6.
Ambarsari CG, Trihono PP, Kadaristiana A, Rachmadi D, Andriastuti M, Puspitasari HA, et al. Low-dose maintenance intravenous iron therapy can prevent anemia in children with end-stage renal disease undergoing chronic hemodialysis. Int J Nephrol. 2020;2020:3067453–8. https://doi.org/10.1155/2020/3067453 .
doi: 10.1155/2020/3067453
pubmed: 32566294
pmcid: 7284959
Hidayati E, Trihono P. Admission characteristics of pediatric chronic kidney disease. Paediatr Indones. 2011;51(4):192–7. https://doi.org/10.14238/pi51.4.2011.192-7 .
doi: 10.14238/pi51.4.2011.192-7
Ambarsari CG, Saraswati M, Laudza GS. Rituximab, mycophenolic acid, and calcineurin inhibitors achieve long-term remission in pediatric focal segmental glomerulosclerosis with steroid-resistant and frequently relapsing nephrotic syndrome: a report of two cases. Case Rep Nephrol Dial. 2022;12:167–77. https://doi.org/10.1159/000525776 .
doi: 10.1159/000525776
pubmed: 36518356
pmcid: 9743143
Santoso DN, Sinuraya FAG, Ambarsari CG. Distal renal tubular acidosis presenting with an acute hypokalemic paralysis in an older child with severe vesicoureteral reflux and syringomyelia: a case report. BMC Nephrol. 2022;23:248. https://doi.org/10.1186/s12882-022-02874-9 .
doi: 10.1186/s12882-022-02874-9
pubmed: 35836135
pmcid: 9284770
Ambarsari CG, Trihono PP, Kadaristiana A, Tambunan T, Mushahar L, Puspitasari HA, et al. Five-year experience of continuous ambulatory peritoneal dialysis in children: a single center experience in a developing country. Med J Indones. 2019;28:329–37. https://doi.org/10.13181/mji.v28i4.3807 .
doi: 10.13181/mji.v28i4.3807
Ambarsari CG, Hidayati EL, Trihono PP, Saraswati M, Rodjani A, Wahyudi I, et al. Experience of the first 6 years of pediatric kidney transplantation in Indonesia: a multicenter retrospective study. Pediatr Transpl. 2020;24(8):e13812. https://doi.org/10.1111/petr.13812 .
doi: 10.1111/petr.13812
Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545–52. https://doi.org/10.1161/CIRCULATIONAHA.108.844506 .
doi: 10.1161/CIRCULATIONAHA.108.844506
pubmed: 19414634
pmcid: 2740903
Voroneanu L, Covic A. Vascular damage in children with chronic kidney disease: the fog is dispersing. Hypertension. 2017;69(5):791–4. https://doi.org/10.1161/HYPERTENSIONAHA.117.08770 .
doi: 10.1161/HYPERTENSIONAHA.117.08770
pubmed: 28373590
Faita F, Gemignani V, Bianchini E, Giannarelli C, Ghiadoni L, Demi M. Real-time measurement system for evaluation of the carotid intima-media thickness with a robust edge operator. J Ultrasound Med. 2008;27(9):1353–61. https://doi.org/10.7863/jum.2008.27.9.1353 .
doi: 10.7863/jum.2008.27.9.1353
pubmed: 18716145
Yang EY, Nambi V. Ultrasound imaging of carotid intima-media thickness: an office-based tool to assist physicians in cardiovascular risk assessment. Curr Atheroscler Rep. 2011;13(5):431–6. https://doi.org/10.1007/s11883-011-0200-5 .
doi: 10.1007/s11883-011-0200-5
pubmed: 21814753
Peters SA, Bots ML. Carotid intima-media thickness studies: study design and data analysis. J Stroke. 2013;15(1):38–48. https://doi.org/10.5853/jos.2013.15.1.38 .
doi: 10.5853/jos.2013.15.1.38
pubmed: 24324938
pmcid: 3779675
Rizikalo A, Coric S, Matetic A, Vasilj M, Tocilj Z, Bozic J. Association of glomerular filtration rate and carotid intima-media thickness in non-diabetic chronic kidney disease patients over a 4-year follow-up. life (Basel). 2021;11(3):204. https://doi.org/10.3390/life11030204 .
doi: 10.3390/life11030204
pubmed: 33807694
Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol. 2014;9(2):344–53. https://doi.org/10.2215/CJN.05840513 .
doi: 10.2215/CJN.05840513
pubmed: 24311704
Rodelo-Haad C, Rodriguez-Ortiz ME, Martin-Malo A, Mier MV, Aguera ML, Munoz-Castaneda JR, et al. Phosphate control in reducing FGF23 levels in hemodialysis patients. PLoS ONE. 2018;13(8):e0201537. https://doi.org/10.1371/journal.pone.0201537 .
doi: 10.1371/journal.pone.0201537
pubmed: 30086150
pmcid: 6080760
Seeherunvong W, Abithol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr Nephrol. 2012;27:2129–36. https://doi.org/10.1007/s00467-012-2224-7 .
doi: 10.1007/s00467-012-2224-7
pubmed: 22710695
Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab. 2010;95(4):1741–8. https://doi.org/10.1210/jc.2009-1576 .
doi: 10.1210/jc.2009-1576
pubmed: 20157196
Waziri B, Duarte R, Naicker S. Chronic kidney disease-mineral and bone disorder (CKD-MBD): current perspectives. Int J Nephrol Renovasc Dis. 2019;12:263–76. https://doi.org/10.2147/IJNRD.S191156 .
doi: 10.2147/IJNRD.S191156
pubmed: 31920363
pmcid: 6935280
Yamada SY, Tokumoto M, Tatsumoto N, Taniguchi M, Noguchi H, Nakano T, et al. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. Am J Physiol Ren Physiol. 2014;306:1418–28. https://doi.org/10.1152/ajprenal.00633.2013 .
doi: 10.1152/ajprenal.00633.2013
Durlacher-Betzer K, Hassan A, Levi R, Axelrod J, Silver J, Naveh-Many T. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int. 2018;94(2):315–25. https://doi.org/10.1016/j.kint.2018.02.026 .
doi: 10.1016/j.kint.2018.02.026
pubmed: 29861060
Ambarsari CG, Sindih RM, Saraswati M, Trihono PP. Delayed admission and management of pediatric acute kidney injury and multiple organ dysfunction syndrome in children with multiple wasp stings: a case series. Case Rep Nephrol Dial. 2019;9:137–48. https://doi.org/10.1159/000504043 .
doi: 10.1159/000504043
pubmed: 31828077
pmcid: 6902257
Feger M, Ewendt F, Strotmann J, Schäffler H, Kempe-Teufel D, Glosse P, et al. Glucocorticoids dexamethasone and prednisolone suppress fibroblast growth factor 23 (FGF23). J Mol Med (Berl). 2021;99(5):699–711. https://doi.org/10.1007/s00109-021-02036-8 .
doi: 10.1007/s00109-021-02036-8
pubmed: 33517471
Liu D, Yang F, Zhang S, Guo Z, Peng S. Significance of changes in FGF23 levels in childhood primary nephrotic syndrome and children who progress to endstage renal disease. Exp Ther Med. 2023;26(2):390. https://doi.org/10.3892/etm.2023.12089 .
doi: 10.3892/etm.2023.12089
pubmed: 37456167
pmcid: 10347369
Bi S, Liang Y, Cheng L, Wang Y, Wang T, Han Q, et al. Hemodialysis is associated with higher serum FGF23 level when compared with peritoneal dialysis. Int Urol Nephrol. 2017;49(9):1653–9. https://doi.org/10.1007/s11255-017-1605-z .
doi: 10.1007/s11255-017-1605-z
pubmed: 28455658
Ambarsari CG, Cahyadi D, Sari L, Satria O, Sahli F, Darmadi TL, et al. Late diagnosis of Lesch-Nyhan disease complicated with end-stage renal disease and tophi disease and tophi burst. Ren Fail. 2020;42(1):113–21. https://doi.org/10.1080/0886022X.2020.1713805 .
doi: 10.1080/0886022X.2020.1713805
pubmed: 31985336
pmcid: 7034128
Balmukhanova A, Kabulbayev K, Alpay H, Kanatbayeva A, Balmukhanova A. FGF-23 and phosphate in children with chronic kidney disease: a cross-sectional study in Kazakhstan. Med (Kaunas). 2020;57(1):15. https://doi.org/10.3390/medicina57010015 .
doi: 10.3390/medicina57010015
Guo AH, Meng JZ, Li DD, Liu WY, Wang SX, Gao F, et al. Adsorptive dialysis for cleaning uremic middle molecular substances. J Clin Rehabil Tissue Eng Res. 2011;15(12):2261–4.
Ambarsari CG, Hidayati EL, Mushahar L, Kadaristiana A. Dressing versus non-dressing technique for long-term exit-site care in children on continuous ambulatory peritoneal dialysis: a single-center retrospective cohort study. Med J Indones. 2020;29(3):290–7. https://doi.org/10.13181/mji.oa.204171 .
doi: 10.13181/mji.oa.204171
Hacıhamdioğlu DÖ, Düzova A, Alehan D, Oğuz B, Beşbaş N. Circulating fibroblast growth factor 23 in children on peritoneal dialysis is associated with effective dialysis. Turk J Pediatr. 2015 Jan-Feb;57(1):9–16. PMID : 26613215.
Isakova T, Xie H, Barchi-Chung A, Vargas G, Sowden N, Houston J, et al. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol. 2011;6(11):2688–95. https://doi.org/10.2215/CJN.04290511 .
doi: 10.2215/CJN.04290511
pubmed: 21903990
pmcid: 3206004
Rabindranath KS, Adams J, Ali TZ, MacLeod AM, Vale L, Cody J, et al. Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease. Cochrane Database Syst Rev. 2007;2007(2):CD006515. https://doi.org/10.1002/14651858.CD006515 .
doi: 10.1002/14651858.CD006515
pubmed: 17443624
pmcid: 6669246
Roumeliotis A, Roumeliotis S, Leivaditis K, Salmas M, Eleftheriadis T, Liakopoulos V. APD or CAPD: one glove does not fit all. Int Urol Nephrol. 2021;53(6):1149–60. https://doi.org/10.1007/s11255-020-02678-6 .
doi: 10.1007/s11255-020-02678-6
pubmed: 33051854
Haarhaus M, Cianciolo G, Barbuto S, La Manna G, Gasperoni L, Tripepi G, et al. Alkaline phosphatase: an old friend as treatment target for cardiovascular and mineral bone disorders in chronic kidney disease. Nutrients. 2022;14(10):2124. https://doi.org/10.3390/nu14102124 .
doi: 10.3390/nu14102124
pubmed: 35631265
pmcid: 9144546
Soeiro EMD, Castro L, Menezes R, Elias RM, Dos Reis LM, Jorgetti V, et al. Association of parathormone and alkaline phosphatase with bone turnover and mineralization in children with CKD on dialysis: effect of age, gender, and race. Pediatr Nephrol. 2020;35(7):1297–305. https://doi.org/10.1007/s00467-020-04499-2 .
doi: 10.1007/s00467-020-04499-2
pubmed: 32157445
Lamb EJ, Delaney MP. Does PTH offer additive value to ALP measurement in assessing CKD-MBD? Perit Dial Int. 2014 Nov-Dec;34(7):687–91. https://doi.org/10.3747/pdi.2014.00246